Mouse IgG3 ELISA Kit

Name: Mouse IgG3 ELISA Kit
SKU: DEIA658
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, Plasma

Species Reactivity

Mouse

Detection Method

Sandwich-ELISA

Intended Use

This enzyme linked immunosorbent assay (ELISA) is for the detection of Mouse IgG3 in serum or plasma. Due to idiotypic and allotypic variations, this product may not accurately quantitate hybridomas, monoclonals or myelomas.

Contents of Kit

No.	Components	Size	Storage Conditions
1	Mouse IgG3 Pre-Coated 96-well Strip Plate	1 each	2-8°C
2	Mouse IgG3 Standard, 1000 ng/vial	2 each	2-8°C
3	Mouse IgG3 Detection Antibody	12 ml	2-8°C
4	10× Dilution Buffer B	25 ml	2-8°C
5	HRP Solution A	12 ml	2-8°C
6	TMB Substrate	12 ml	2-8°C
7	Stop Solution	12 ml	2-8°C
8	20× Wash Buffer	50 ml	2-8°C
9	Sealing Tape	6 sheets

Storage

Stored at 2-8°C for 6 months from date of receipt.

General Description

There are five classes of mammalian immunoglobulins: IgA, IgD, IgE, IgG, and IgM. In mice, the IgG class is further divided into four subclasses: IgG1, IgG2a/ IgG2c (strain specific), IgG2b, and IgG3.The general immunoglobulin structure is described as two heavy and two light chain (H2L2) polypeptides linked together by disulfide bridges of cysteine residues. Mouse IgG3 appears early in the immune response independently of T cell help and as such, is an early effecter of the immune system (Abdelmoula et al., 1989). Mouse IgG3 is not a homologue of Human IgG3 (Stack, J. et al, 1980). Mouse IgG3 is also important in the resistance of pathogens (Briles et al. 1981)) and is involved in the pathogenic processes of autoimmune disease, especially immune complex precipitation and glomerulonephritis (Abdelmoula et al., 1989). IgG3 is also known to cross the placenta (Greenspan & Cooper, 1992). Mouse IgG3 has a very long half-time (t1/2 = 4 days) but is found in low concentrations in the serum (Quimby & Luong Richard, 2007).

Standard Curve

This typical standard curve was generated using the Mouse IgG3 ELISA Kit Protocol. This standard curve is for demonstration only. A standard curve must be generated for each assay.

*Suggested standard curve points are 1000 ng/ml, 333, 111, 37, 12.3, 4.1 1.37, and 0 ng/ml. Assay Range: 1.37 – 1000 ng/ml

Citations

Have you cited DEIA658 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

Immunoassays for Process-related Impurities

QA & Reviews

Customer Reviews

References

Long-term effects of intensive B cell depletion therapy in severe cases of IgG4-related disease with renal involvement

IMMUNOLOGIC RESEARCH

Authors: Quattrocchio, Giacomo; Barreca, Antonella; Demarchi, Andrea; Fenoglio, Roberta; Ferro, Michela; Del Vecchio, Giulio; Massara, Carlo; Rollino, Cristiana; Sciascia, Savino; Roccatello, Dario

Abstract

IgG4-related disease (IgG4-RD) is an immune-mediated disorder often showing elevated serum IgG4 concentrations, dense T and B lymphocyte infiltration, and IgG4-positive plasma cells and storiform fibrosis. We prospectively evaluated for 4 years 5 patients with histologically proven IgG4-RD of whom 3 had tubulointerstitial nephritis (TIN) and 2 had retroperitoneal fibrosis (RPF). They received an intensive B depletion therapy with rituximab. The estimated glomerular filtration rate of TIN patients after 1 year increased from 9 to 24 ml/min per 1.73 m2. IgG/IgG4 dropped from 3236/665 to 706/51 mg/dl, C3/C4 went up from 49/6 to 99/27 mg/dl, and the IgG4-RD responder index fell from 10 to 1. CD20(+) B cells decreased from 8.7 to 0.5%. A striking drop in interstitial plasma cell infiltrate as well as normalization of IgG4/IgG-positive plasma cells was observed at repeat biopsy. Both clinical and immunological improvement persisted over a 4-year follow-up. Treating these patients who were affected by aggressive IgG4-RD with renal involvement in an effort to induce a prolonged B cells depletion with IgG4 and cytokine production decrease resulted in a considerable rise in eGFR, with IgG4-RD RI normalization and a noteworthy improvement in clinical and histological features. Furthermore, the TIN subgroup was shown not to need for any maintenance therapy.

Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation - A Single Centre Study

ANTICANCER RESEARCH

Authors: Studer, Ursina; Khanna, Nina; Leuzinger, Karoline; Hirsch, Hans H.; Heim, Dominik; Lengerke, Claudia; Tsakiris, Dimitrios A.; Halter, Joerg; Gerull, Sabine; Passweg, Jakob; Medinger, Michael; Gwerder, Malena

Abstract

Background/Aim: Cytomegalovirus (CMV) replication may cause life-threatening complications after allogeneic haematopoietic stem cell transplantation (allo-HSCT). The aim of the study was to characterize CMV events, and the outcome of letermovir (LTV) CMV prophylaxis. Patients and Methods: In this retrospective analysis of patients treated with an allo-HSCT between 2010 and 2020, we determined plasma CMV events, as well as associated risk factors. Results: We identified 423 patients who had undergone allo-HSCT between 2010 and 2020. CMV DNAemia was found in 130/423 (30.7%) of patients. CMV reactivation rate was significantly higher in patients with acute graft-versus-host disease, HLA mismatch, and CMV IgG seropositivity of donors and recipients. Among 42 patients receiving LTV prophylaxis those, 5 (11.9%) showed CMV DNAemia under LTV versus 87/353 (24.6%) in a control group. Conclusion: Despite the development of better approaches with weekly monitoring and early treatment initiation, CMV reactivations play an important role after allo-HSCT.